Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David F McDermott

Showing results (31-40 of 227) with videos related to

Pageof 23
Sort By:
Clinical Therapeutics|April 1, 2015
The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in MelanomaKathleen M Mahoney, Gordon J Freeman, David F McDermott
Clinical Genitourinary Cancer|October 10, 2006
Interleukin-2 therapy of metastatic renal cell carcinoma: update of phase III trialsDavid F McDermott, Meredith M Regan, Michael B Atkins
Nature Reviews. Clinical Oncology|April 28, 2026
The clinical landscape of HIF2α inhibitors in oncologyEddy Saad, Marc Machaalani, David F McDermott, et al.
Clinical Genitourinary Cancer|March 8, 2020
Combining Immune Checkpoint and VEGFR Inhibition in Favorable Risk and Elderly Patients With Metastatic Renal Cell CarcinomaAndreas Varkaris, Wenxin Xu, Roger B Davis, et al.
BJU International|February 16, 2011
Addition of gemcitabine at the time of sunitinib resistance in metastatic renal cell cancerShuchi S Pandya, James W Mier, David F McDermott, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|August 23, 2005
Histologic predictors of renal cell carcinoma response to interleukin-2-based therapyMelissa P Upton, Robert A Parker, Amanda Youmans, et al.
European Urology Focus|July 6, 2025
KIM-1 as a Prognostic Marker in Renal Cell CarcinomaClara Steiner, Marc Machaalani, Joseph V Bonventre, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 16, 2024
Metastasis-Free Survival Versus Treatment-Free Survival in Biochemically Recurrent Prostate Cancer: The EMBARK TrialDavid J Einstein, Meredith M Regan, Julia S Stevens, et al.
Clinical Genitourinary Cancer|February 14, 2009
Phase II trial of carboplatin and paclitaxel in papillary renal cell carcinomaKathryn A Bylow, Michael B Atkins, Edwin M Posadas, et al.
Journal of the American College of Cardiology|September 5, 2015
Vascular and Metabolic Implications of Novel Targeted Cancer Therapies: Focus on Kinase InhibitorsWeijuan Li, Kevin Croce, David P Steensma, et al.
Pageof 23

Showing results (31-40 of 227) with videos related to

Sort By:
Pageof 23
Clinical Therapeutics|April 1, 2015
The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in MelanomaKathleen M Mahoney, Gordon J Freeman, David F McDermott
Clinical Genitourinary Cancer|October 10, 2006
Interleukin-2 therapy of metastatic renal cell carcinoma: update of phase III trialsDavid F McDermott, Meredith M Regan, Michael B Atkins
Nature Reviews. Clinical Oncology|April 28, 2026
The clinical landscape of HIF2α inhibitors in oncologyEddy Saad, Marc Machaalani, David F McDermott, et al.
Clinical Genitourinary Cancer|March 8, 2020
Combining Immune Checkpoint and VEGFR Inhibition in Favorable Risk and Elderly Patients With Metastatic Renal Cell CarcinomaAndreas Varkaris, Wenxin Xu, Roger B Davis, et al.
BJU International|February 16, 2011
Addition of gemcitabine at the time of sunitinib resistance in metastatic renal cell cancerShuchi S Pandya, James W Mier, David F McDermott, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|August 23, 2005
Histologic predictors of renal cell carcinoma response to interleukin-2-based therapyMelissa P Upton, Robert A Parker, Amanda Youmans, et al.
European Urology Focus|July 6, 2025
KIM-1 as a Prognostic Marker in Renal Cell CarcinomaClara Steiner, Marc Machaalani, Joseph V Bonventre, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 16, 2024
Metastasis-Free Survival Versus Treatment-Free Survival in Biochemically Recurrent Prostate Cancer: The EMBARK TrialDavid J Einstein, Meredith M Regan, Julia S Stevens, et al.
Clinical Genitourinary Cancer|February 14, 2009
Phase II trial of carboplatin and paclitaxel in papillary renal cell carcinomaKathryn A Bylow, Michael B Atkins, Edwin M Posadas, et al.
Journal of the American College of Cardiology|September 5, 2015
Vascular and Metabolic Implications of Novel Targeted Cancer Therapies: Focus on Kinase InhibitorsWeijuan Li, Kevin Croce, David P Steensma, et al.
Pageof 23